Mirati Therapeutics, Inc. (MRTX) Analysts See $-0.77 EPS

October 14, 2018 - By Darrin Black

Mirati Therapeutics, Inc. (NASDAQ:MRTX) LogoInvestors sentiment increased to 2.38 in Q2 2018. Its up 0.62, from 1.76 in 2018Q1. It increased, as 20 investors sold Mirati Therapeutics, Inc. shares while 12 reduced holdings. 50 funds opened positions while 26 raised stakes. 25.75 million shares or 31.83% more from 19.53 million shares in 2018Q1 were reported.
Credit Suisse Ag stated it has 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Sio Lc holds 1.64% or 60,050 shares. New York-based Art Advsr Limited Liability has invested 0.06% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Bvf Incorporated Il reported 3.58% stake. Federated Invsts Pa has 34,099 shares for 0% of their portfolio. Schwab Charles Inv Management invested in 43,257 shares or 0% of the stock. Farallon Capital Management Limited Company, a California-based fund reported 743,500 shares. Morgan Stanley invested 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Voya Invest Mngmt Limited Liability Company invested in 7,029 shares or 0% of the stock. Bnp Paribas Arbitrage Sa reported 0% stake. Ghost Tree Limited Com stated it has 500,000 shares. Goldman Sachs invested in 0% or 47,294 shares. Bancorporation Of America De holds 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX) or 33,719 shares. Bluemountain Cap Mgmt Limited Liability Company owns 5,347 shares. Thompson Davis And reported 1,250 shares.

Since June 7, 2018, it had 2 insider buys, and 2 sales for $19.56 million activity. 10,207 shares were sold by Christensen Jamie, worth $501,630 on Tuesday, June 26. BAUM CHARLES M also sold $2.98M worth of Mirati Therapeutics, Inc. (NASDAQ:MRTX) shares. Shares for $7.50M were bought by Boxer Capital – LLC on Thursday, June 7.

Analysts expect Mirati Therapeutics, Inc. (NASDAQ:MRTX) to report $-0.77 EPS on November, 7.They anticipate $0.12 EPS change or 18.46 % from last quarter’s $-0.65 EPS. After having $-0.94 EPS previously, Mirati Therapeutics, Inc.’s analysts see -18.09 % EPS growth. The stock increased 5.08% or $2.06 during the last trading session, reaching $42.58. About 368,961 shares traded. Mirati Therapeutics, Inc. (NASDAQ:MRTX) has risen 1024.49% since October 14, 2017 and is uptrending. It has outperformed by 1008.87% the S&P500.

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company has market cap of $1.38 billion. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. It currently has negative earnings. The Company’s clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC.

More recent Mirati Therapeutics, Inc. (NASDAQ:MRTX) news were published by: Nasdaq.com which released: “3 Biotech Stocks With Major Incoming Catalysts” on October 09, 2018. Also Seekingalpha.com published the news titled: “Key events next week – healthcare” on October 12, 2018. 247Wallst.com‘s news article titled: “Major Biopharma Catalysts to Watch For in October” with publication date: October 06, 2018 was also an interesting one.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>